The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.
 
Lingying Wu
No Relationships to Disclose
 
Peng-Hui Wang
No Relationships to Disclose
 
Sheng-Yen Hsiao
No Relationships to Disclose
 
Chih-Long Chang
No Relationships to Disclose
 
Hee Seung Kim
No Relationships to Disclose
 
JUNG-YUN LEE
Consulting or Advisory Role - AstraZeneca; MSD; Roche; Takeda
Research Funding - AstraZeneca; Clovis Oncology (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); MSD; MSD (Inst); Synthon (Inst)
 
Sang-Young Ryu
No Relationships to Disclose
 
Yunxia Zuo
Employment - BeiGene; BeiGene (I); Hengrui Medicine; Hengrui Medicine (I)
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene; BeiGene (I); Hengrui Medicine; Hengrui Pharmaceutical (I)
 
Xiyan Mu
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Yujuan Gao
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Silu Yang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Honoraria - BeiGene
 
Jae-Kwan Lee
No Relationships to Disclose